Axovant Sciences Ltd (NASDAQ:AXON)’s share price rose 6.5% during mid-day trading on Wednesday . The stock traded as high as $1.15 and last traded at $1.14. Approximately 1,163,168 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 1,469,978 shares. The stock had previously closed at $1.07.
AXON has been the subject of several research analyst reports. Cowen restated a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. Axovant Sciences currently has a consensus rating of “Hold” and an average price target of $3.81.
The company has a market capitalization of $139.40 million, a price-to-earnings ratio of -0.56 and a beta of 1.22. The company has a debt-to-equity ratio of 1.68, a quick ratio of 1.97 and a current ratio of 1.97.
Axovant Sciences (NASDAQ:AXON) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.10. Research analysts expect that Axovant Sciences Ltd will post -1.25 earnings per share for the current fiscal year.
In other Axovant Sciences news, major shareholder Svf Investments (Uk) Ltd bought 10,000,000 shares of the firm’s stock in a transaction dated Tuesday, December 18th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider now owns 99,285,714 shares of the company’s stock, valued at $99,285,714. The acquisition was disclosed in a filing with the SEC, which is available through this link. 6.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in Axovant Sciences by 60.5% during the third quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after purchasing an additional 788,100 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after purchasing an additional 64,152 shares in the last quarter. BlackRock Inc. raised its holdings in Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after purchasing an additional 169,918 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 58,541 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in Axovant Sciences during the second quarter worth about $356,000. 7.71% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Axovant Sciences (AXON) Stock Price Up 6.5%” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thelincolnianonline.com/2019/01/11/axovant-sciences-axon-stock-price-up-6-5.html.
Axovant Sciences Company Profile (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.